Evidence-based cannabis information for adults 50 and older Peer-reviewed citations · Always talk to your doctor or pharmacist · No product sales

Cannabis with Benzodiazepines and Opioids — Compounded Risk

Sedation compounding raises fall and respiratory-depression risk. The Epidiolex/clobazam interaction, the dual-edge of opioid-sparing, and what supervised tapering looks like.

Two Pathways, One Compounded Risk

Cannabis interacts with sedative medications through two distinct mechanisms that reinforce each other — making this interaction category among the most dangerous for older adults. Strong evidence

The first pathway is pharmacokinetic: CBD inhibits the liver enzymes that metabolize benzodiazepines and opioids, causing these drugs to accumulate in the bloodstream at higher-than-intended levels. The second is pharmacodynamic: both cannabis and sedatives depress the central nervous system, so their combined effects on drowsiness, coordination, and respiratory drive are additive — sometimes synergistic.

For seniors, this combination carries an outsized consequence: falls are the leading cause of injury-related death in adults over 65. Any increase in sedation, dizziness, or impaired balance translates directly into increased fall risk — and if that senior also takes blood thinners, even a minor fall can produce disproportionate bleeding.

Benzodiazepines: Alprazolam, Clonazepam, Diazepam

The three most commonly prescribed benzodiazepines in older adults — alprazolam (Xanax), clonazepam (Klonopin), and diazepam (Valium) — are all metabolized by CYP3A4. CBD is a potent inhibitor of this enzyme. When CBD slows CYP3A4 activity, benzodiazepine blood levels can rise, intensifying sedation, cognitive impairment, and motor incoordination.

The Clobazam Evidence: A Threefold Metabolite Increase

The best-documented cannabis-benzodiazepine interaction comes from Epidiolex (pharmaceutical-grade CBD) clinical trials. CBD increased the active metabolite of clobazam — N-desmethylclobazam — by approximately threefold via CYP2C19 inhibition. Patients experienced increased somnolence and sedation at these elevated metabolite levels. Strong evidence

The clinical significance was clear enough that the FDA Epidiolex prescribing information now recommends clobazam dose reduction during co-administration. While clobazam is primarily used for epilepsy rather than anxiety, the interaction illustrates the magnitude of CBD's enzyme-inhibiting effects on the benzodiazepine class.

Opioids: A Dual-Edged Interaction

The cannabis-opioid interaction presents a clinical paradox: it is dangerous in unmonitored settings but potentially beneficial under clinical supervision.

The Risks

Commonly prescribed opioids — hydrocodone, oxycodone, and tramadol — are metabolized by CYP2D6, which CBD inhibits. This can slow opioid clearance and raise blood levels. Combined with the additive CNS depression from both substances, the risks include:

  • Excessive sedation leading to falls
  • Respiratory depression — slowed breathing that can become dangerous
  • Cognitive impairment that impairs judgment about one's own level of impairment

The Potential Benefits

Research by Dr. Donald Abrams, Professor Emeritus at UCSF, found that combining cannabis and morphine improved analgesic effects. The mechanism may involve delayed gastrointestinal motility — cannabis slows gut transit, potentially creating a sustained-release effect for oral opioids that extends pain relief.

This finding has fueled interest in opioid-sparing strategies: using cannabis to reduce the opioid dose needed for adequate pain control, potentially lowering the risk of opioid dependence. However, this approach requires careful physician supervision, dose titration, and monitoring — it is not something patients should attempt independently.

The Falls Connection

The clinical stakes of sedative interactions in older adults come down to one word: falls. Falls are the leading cause of injury-related death in adults over 65 and the most common cause of traumatic brain injury in this age group.

Cannabis alone measurably increases fall risk — a 2021 study by Workman, Sosnoff, and Rudroff in Brain Sciences found that chronic cannabis users over 50 had worse one-leg balance, slower gait, and a dangerous disconnect between perceived and actual fall risk. Layer a benzodiazepine or opioid on top of cannabis-induced impairment, and the fall risk compounds significantly.

If a senior is also taking blood thinners, the cascade worsens further: cannabinoid-anticoagulant interactions can elevate INR, meaning even a minor fall-related injury can produce disproportionate bleeding. See Blood Thinners for the full evidence.

Risk Reduction Strategies

If your physician determines that cannabis may be appropriate alongside a benzodiazepine or opioid, these precautions can reduce — but not eliminate — risk:

  1. Inform every prescriber. Your physician managing the sedative prescription, your pharmacist, and your cannabis provider all need to know the full picture.
  2. Start at nighttime only. If sedation is the primary risk, initial cannabis use while already in bed for the night reduces fall exposure.
  3. Ensure a fall-proof environment. Remove throw rugs, install grab bars, keep nightlights on paths to the bathroom, and have a phone within reach.
  4. Have someone present. During the first several sessions combining cannabis with a sedative medication, another person should be in the home.
  5. Use the lowest effective dose of both. The start low, go slow principle is doubly important when sedatives are in the mix.
  6. Separate dosing times. Taking cannabis and a benzodiazepine or opioid at the same time produces the highest peak interaction. Spacing them apart by several hours may reduce — though not eliminate — compounded sedation.
  7. Monitor for warning signs. Unusual drowsiness, confusion, unsteady gait, or feeling "foggy" the morning after use are signals that the combination may be too sedating at current doses.